The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...

GSK’s Arexvy and Pfizer’s Abrysvo are the top-selling RSV vaccines for older adults and will be joined in the next RSV season by Moderna’s recently approved mRESVIA. Meanwhile, Sanofi and AZ ...

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.